The DOI matches its Crossref record.
Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, G418 and NB124 can stably promote the expression of full-length p53 protein.558,559”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [559]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 42
- 10.1016/j.tig.2008.08.010 · DOI · Paper page
- 10.1038/nrg2402 · DOI · Paper page
- 10.1038/nature13737 · DOI · Paper page
- 10.1146/annurev-genom-091212-153527 · DOI · Paper page
- 10.1093/nar/gkq1277 · DOI · Paper page
- 10.1038/mt.2013.150 · DOI
- 10.1084/jem.20081940 · DOI
- 10.1038/nature05756 · DOI · Paper page
- 10.1016/j.nmd.2014.11.011 · DOI · Paper page
- 10.1159/000013861 · DOI · Paper page
- 10.1021/jm3012992 · doi:10.1021/jm3012992
- 10.1073/pnas.1204073109 · DOI · Paper page
- 10.1074/jbc.M113.533588 · DOI
- 10.1165/rcmb.2013-0282OC · DOI
- 10.1006/bbrc.1999.1446 · DOI
- 10.1101/gad.12.19.2973 · DOI · Paper page
- 10.1101/gad.10.9.1054 · DOI · Paper page
- 10.1159/000066755 · DOI · Paper page
- 10.1039/C4MD00081A · DOI
- 10.1002/emmm.201201438 · DOI
- 10.1002/humu.20210 · DOI
- 10.1371/journal.pgen.1002608 · DOI
- 10.1016/S0165-4608(99)00253-8 · doi:10.1016/s0165-4608(99)00253-8
- 10.1146/annurev-genet-111212-133424 · DOI · Paper page
- 10.1002/jgm.1140 · DOI
- 10.1002/cbic.200700271 · DOI
- Gotz C, 1995, Int J Oncol, 6, 1129
- 10.1101/gad.10.19.2438 · DOI · Paper page
- 10.1074/jbc.273.50.33533 · DOI · Paper page
- 10.1038/nbt0913-771 · doi:10.1038/nbt0913-771
- 10.1038/nbt0814-706 · DOI
- 10.1164/rccm.201601-0154OC · DOI
- 10.1021/acsmedchemlett.6b00006 · doi:10.1021/acsmedchemlett.6b00006
- 10.1021/jm801640k · DOI · Paper page
- 10.1016/j.bmc.2010.03.060 · DOI
- 10.1038/nature14896 · DOI · Paper page
- 10.1038/ncomms10457 · DOI · Paper page
- 10.1038/ncomms8251 · DOI
- 10.1172/JCI28523 · DOI · Paper page
- 10.1093/nar/gku663 · DOI
- 10.1038/sj.gt.3302211 · DOI
- 10.1093/nar/23.9.1557 · DOI
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
Metadata
- Authors
- Bidou, L., Bugaud, O., Belakhov, V., Baasov, T., & Namy, O.
- Affiliations
- Université Pierre et Marie Curie, Paris, France
- Institute for Integrative Biology of the Cell (I2BC), CEA, CNRS, Univ Paris Sud, Université Paris-Saclay, Gif sur Yvette cedex, France
- Edith and Joseph Fischer Enzyme Inhibitors Laboratory, Schulich Faculty of Chemistry Technion IIT, Haifa, Israel
- ORCID
- Namy, Olivier
- Venue
- RNA Biology
- Publisher
- Informa UK Limited
- Published
- 2017-02-23
- Volume
- 14
- Issue
- 3
- Pages
- 378-388
- ISSN
- 1547-6286
- 1555-8584
- Cited by
- 101
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. https://app.cochat.ai/papers/10.1080/15476286.2017.1285480
- The paper
- Bidou, L., Bugaud, O., Belakhov, V., Baasov, T., & Namy, O. (2017). Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. RNA Biology. https://doi.org/10.1080/15476286.2017.1285480
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.